Skip to content
Dosage GuideResearch Reference

FGL Peptide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for FGL Peptide. All information is for educational purposes only.

Quick Answer

While no human clinical trials exist to establish optimal dosing, preclinical research in rodents suggests a dose range of 0.1-1 mg/kg. Converting this to human equivalent doses (HED) using a body surface area conversion suggests potential ranges of 1.6-16.2 mg for a 70 kg individual. However, this is purely theoretical. Animal studies primarily utilize intraperitoneal or subcutaneous injection.

→ FGL Peptide Benefits→ FGL Peptide Side Effects→ Full FGL Peptide Profile
Table of Contents

Standard Dosage Range

Research dosing range: No established human range. Rodent models suggest ~1.6-16.2 mg HED for a 70kg individual (theoretical).

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Cognitive Enhancement

Theoretical: 1.6-8 mg (HED for 70kg)1× daily
Duration

4–12 weeks

No human data. Animal models used intraperitoneal or subcutaneous injections. Oral bioavailability is unknown.

Neuroprotection (Alzheimer's model)

Theoretical: 2-16.2 mg (HED for 70kg)1× daily
Duration

4–12 weeks

Based on rodent models using intraperitoneal injections. Consider starting at the lower end of the range.

Anti-inflammatory (CNS)

Theoretical: 1.6-4 mg (HED for 70kg)1× daily
Duration

4–8 weeks

Derived from rodent studies. May be lower than cognitive enhancement dosages. Administration method is unknown in humans.

Timing & Frequency

No human studies exist. Animal studies administer FGL peptide once daily. The optimal timing of administration in relation to activity/sleep is currently unknown.

Cycle Guidance

Due to the absence of human data, cycle guidance is speculative. Based on animal research durations, cycles of 4-12 weeks followed by a break of equivalent duration may be considered. The long-term effects of continuous FGL peptide exposure are unknown.

Reconstitution Reference

Quick reference for reconstituting FGL Peptide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVaries. Typically 1-5 mg per vial.
BAC Water VolumeConsult manufacturer specifications for optimal concentration.
Concentration & DrawVariable depending on vial size and water volume. Calculate to achieve desired dosage per injection volume.
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution stable for a limited time refrigerated. Refer to manufacturer specifications. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the appropriate dosage for FGL peptide?
There are no established human dosages for FGL peptide. Dosages used in animal models, when converted to human equivalent doses, suggest a theoretical range of 1.6-16.2 mg for a 70 kg individual. However, this is only a theoretical calculation and should not be interpreted as a recommended dosage. Further research is needed.
Is FGL peptide safe?
The safety profile of FGL peptide has not been established in humans. Preclinical studies in rodents have not reported significant adverse effects, but these findings cannot be directly extrapolated to humans. It is essential to proceed with caution and consult with a healthcare professional before considering FGL peptide.

Last updated: 2026-02-19